Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32866033.
- Also identified by DOI 10.1164/rccm.202005-1885OC and PMC identifier 7706149.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>Rationale:</b> Uncontrolled inflammatory innate response and impaired adaptive immune response are associated with clinical severity in patients with coronavirus disease (COVID-19).<b>Objectives:</b> To compare the immunopathology of COVID-19 acute respiratory distress syndrome (ARDS) with that of non-COVID-19 ARDS, and to identify biomarkers associated with mortality in patients with COVID-19 ARDS.<b>Methods:</b> Prospective observational monocenter study. Immunocompetent patients diagnosed with RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and ARDS admitted between March 8 and March 30, 2020, were included and compared with patients with non-COVID-19 ARDS. The primary clinical endpoint of the study was mortality at Day 28. Flow cytometry analyses and serum cytokine measurements were performed at Days 1-2 and 4-6 of ICU admission.<b>Measurements and Main Results:</b> As compared with patients with non-COVID-19 ARDS (<i>n</i> = 36), those with COVID-19 (<i>n</i> = 38) were not significantly different regarding age, sex, and Sequential Organ Failure Assessment and Simplified Acute Physiology Score II scores but exhibited a higher Day-28 mortality (34% vs. 11%, <i>P</i> = 0.030). Patients with COVID-19 showed profound and sustained T CD4<sup>+</sup> (<i>P</i> = 0.002), CD8<sup>+</sup> (<i>P</i> < 0.0001), and B (<i>P</i> < 0.0001) lymphopenia, higher HLA-DR expression on monocytes (<i>P</i> < 0.001) and higher serum concentrations of EGF (epithelial growth factor), GM-CSF, IL-10, CCL2/MCP-1, CCL3/MIP-1a, CXCL10/IP-10, CCL5/RANTES, and CCL20/MIP-3a. After adjusting on age and Sequential Organ Failure Assessment, serum CXCL10/IP-10 (<i>P</i> = 0.047) and GM-CSF (<i>P</i> = 0.050) were higher and nasopharyngeal RT-PCR cycle threshold values lower (<i>P</i> = 0.010) in patients with COVID-19 who were dead at Day 28.<b>Conclusions:</b> Profound global lymphopenia and a "chemokine signature" were observed in COVID-19 ARDS. Increased serum concentrations of CXCL10/IP-10 and GM-CSF, together with higher nasopharyngeal SARS-CoV-2 viral load, were associated with Day-28 mortality.
Medical subject headings
- Adult
- Aged
- Antibodies, Viral/blood
- COVID-19/blood
- COVID-19/epidemiology
- COVID-19/immunology
- COVID-19/physiopathology
- Chemokines/blood
- Female
- France/epidemiology
- Humans
- Immunity, Innate
- Male
- Middle Aged
- Pandemics
- Prospective Studies
- Respiratory Distress Syndrome/blood
- Respiratory Distress Syndrome/epidemiology
- Respiratory Distress Syndrome/immunology
- Respiratory Distress Syndrome/physiopathology
- Viral Load